Calcium-Binding Proteins from Colubrid Venom Multiple proteins with calcium-binding capacity have been detected in the venom glands of several South American snakes belonging to the families Colubridae, Elapidae and Viperidae.[119] A parvalbumin 12 kD ; was common to all glands studied and was the only calcium-binding protein CaBP ; found in the Duvernoy's gland of the colubrid Oxyrhopus trigeminus. Three additional CaBPs 17, 28 and 67 kD ; were seen in blots of gland homogenate from the colubrid Philodryas patagoniensis. No CaBPs were detected in secreted colubrid or elapid venoms analyzed, and the role of these proteins to venom or venom gland function is not clear. However, numerous calciumrequiring enzymes are known to be present in snake venoms e.g., PLA2, some proteases, etc. ; , and in snake venom glands, the CaBPs may be involved in regulation of secretion, as is observed in other glands.[120].

147. Otsuka America Pharmaceutical, Inc., Pharmacia & Upjohn Corp. [Internet]. Pketal prescribing information package insert ; . [Cited 2002 Oct]. Available at : pletal pro 0 7 . 148. Aventis Pharmaceutical, Inc. [Internet]. Trental prescribing information package insert ; . [Cited 2002 Oct]. Available at : aventisus PIs trental TXT . 149. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12: 209-15. Levy PJ, MacClenahan K, Ferrario CM, Yunis C. Secondary prevention is inferior in patients with peripheral arterial disease. J Coll Cardiol 2002; 39: Suppl A. Abstract: 1179-79. [Internet]. Available at : cardiosource library journals journal accabstracts?sdid 4884. 151. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions. Insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative PVD-QI2 ; . Circulation 2002; 106 15 ; : 1909-12. Abstract. 152. Mulkay KT, Benjamin ME, Lilly MP, et al. The prevalence of lipid lowering therapy in patients undergoing infrainguinal bypass. The Society for Vascular Medicine and Biology. 12th Annual Meeting & Postgraduate Symposium. Poster presentation P16. [Internet]. Available at : svmb medpro events annualmeeting meeting3 . 153. Nass CM, Allen JK, Jermyn RM, Fleisher LA. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. Vasc Med 2001; 6: 35-41. Adams PF, Hendershot GE, Marano MA. Current estimates form the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat 10 200 ; . 1999. 155. 2002 Drug Topics Red Book. Montvale NJ ; . Thompson Medical Economics; 2002. 156. Kaplan NM. Angiotensin II receptor antagonists in the treatment of hypertension. Fam Physician 1999; 60 4 ; : 1185-90. 157. Ward MR, Pasterkamp G, Yeung AC, Borst C. Arterial remodeling mechanisms and clinical implications. Circulation 2000; 102: 1186-91. Much of early learning involves the learning of language, during which time learning and learning language are often indistinguishable. As language is learned it then becomes used as the tool through which other learning takes place. Among this other learning is the reflection on language itself. Language is therefore inextricably connected to all learning and most learning, and all higher learning, is deeply dependent on language. The sequence has often been identified as Learning Language, Learning through Language and then Learning about Language, though there are not tight boundaries between these characterisations. Prior to schooling children do an immense amount of learning, much of it devoted to acquiring the code, at least in its oral form, which will constitute the tool of most schooling. However, from an early age children are learning about print, and writing, and other symbolic characterisations of language, and other languages. In Australia, and more so in Victoria than other Australian states, children are also learning in, through and about languages other than English. There are considerable numbers of young Victorians who are also learning in through and about two languages, and who therefore have two mother tongues. It is important to appreciate at the outset of a discussion paper on languages that Australian families are very linguistically diverse and that Victorian children come to school with a wide array of knowledge about, proficiency in, and attitudes towards languages, including English and a large number of other languages. Educational efforts to encourage more children to encounter languages other than English in pre-school, in child-care, in kindergarten and in other settings of care and education prior to formal compulsory schooling are important. These efforts are important because young children are likely to be more receptive and in some ways ultimately more successful in their acquisition of languages from an early age. This, as will be argued repeatedly in the present document is intrinsically worthwhile because languages are essential markers of human diversity, identity, and of the organisation of society, Australia's as well as all others, but also because this encounter with multilingualism, particularly if it results in enhanced proficiency gains will significantly and positively impact of children's general academic and cognitive growth. The pre-school language experiences of children are not only significant in terms of how they prepare the ground for subsequent learning. Each stage of learning language, learning about language and the quality and depth of learning through language is intrinsically important. Developmental processes in the acquisition of language effect constraints on what is most readily learned at each stage and phase of education. Therefore what is particular about the language and learning possibilities at each age level of children, meaning the relation between acquired language skill and potential and zerit.

The following Items were added to the LMHS In-Patient Formulary: Plftal Cilostazol ; Pleral is indicated for the treatment of intermittent claudication. Pletal should NOT be used in patients with CHF. Perforomist formoterol ; Solution Perforomist formoterol ; solution fornebulization is a long acting beta-2 agonist bronchodilator ; . This is an addition to LMHS formulary as Foradil formoterol ; powder for inhalation is already a formulary item. Travatan Travoprost ; Eye Drops Indicated for raised intraocular pressure in patients with open-angle glaucoma or ocular hypertension Lumigan Bimatoprost ; Eye Drops Indicated for open-angle glaucoma with raised intraocular pressure and ocular hypertension with raised intraocular pressure. The following items have been removed from the LMHS In-Patient Formulary: IV Colchicine, Trasylol, 10% Lipidsme Advair Symbicort discus ; Therapeutic Substitution There will be no automatic substitution of Advair discus to Symbicort discus. Both Advair and Symbicort are on formulary and will be available as ordered with no substitution. For additional information please see the P&T newsletter or contact Sandy Estrada, Pharm.D. sandy trada leememorial.
DISCUSSION After passing through the cavernous sinus, the IIIrd, IVth, rst branch of the Vth, and the VIth cranial nerves enter the orbit through the superior orbital ssure 7 ; . The optic nerve, along with the ophthalmic artery, enters the orbit through the optic canal. If an inammatory process involves the orbital apex, it interrupts the nerves at a critical juncture, i.e., the bony canals, and can cause complete ophthalmoplegia, loss of vision, and decreased ocular sensations the orbital apex syndrome ; . In addition, inammatory processes associated with systemic vasculitis may affect the ophthalmic, posterior ciliary, or central retinal artery, thereby causing abrupt onset of blindness, while inammation of the connective tissue around the blood vessels can produce proptosis 7 ; . Involvement of the ophthalmic artery, particularly, will produce ocular ischemia, while that of the ciliary or central retinal artery causes posterior segment ischemia. In orbital apex syndrome, when there is massive loss of vision, bony destruction, and large elevation of ESR, one must look for a systemic vasculitis 7 ; . While vasculitis due to Wegener's granulomatosis and periarteritis nodosa has been implicated in orbital apex syndrome 7, 14 ; , it has not been described as a cause due to ENL in current literature and epivir-hbv.

Across: 1 Cafe; 3 Precious; 8 Tire; 9 Abundant; 11 Have a flutter; 13 Normal; 14 Strike; 17 Substantiate; 20 Epidemic; 21 Dive; 22 Prestige; 23 Deny. Down: 1 Catching; 2 Forever; 4 Rabble; 5 Constitute; 6 Orate; 7 Sate; 10 Harassment; 12 Cemetery; 15 Imagine; 16 Daring; 18 Unite; 19 Deep.
Adjunct to ASA in stent placement percutaneous coronary intervention ; or in patients with unstable angina. Plavix Clopidogrel ; may be better as 1st line treatment for chronic extremity arterial insufficiency. In addition, ACCP guidelines recommend Pletal cilostazol ; for patients experiencing disabling claudication when revascularization cannot be performed, not recommended for routine use in intermittent claudication. Sustained Release Oral Opioid Agonist Diagnosis and ICD-9 code are required for this drug class see Section Five: Drug Clinical Information ; . Approval may be given for the treatment of intractable, chronic pain with oral SR opioid agonists OxyContin, Kadian, Oramorph SR, MS Contin, AvinzaTM ; . These medications are narcotic analgesics and Schedule II controlled substances. They are not intended for use with acute pain, as a PRN analgesic or for short-term pain management 10 days ; . The patient must have had failed 30 day trials with alternative pain management therapies and non-opioid adjuvant drugs to replace or enhance opioid analgesia, unless the primary diagnosis is an approved cancer diagnosis. Submission of a plan of action addressing continued medical monitoring, titration and a written signed contract for therapy is required for patients with a history of substance abuse or addiction, unless the patient is a nursing home resident. For nursing home residents with a history of substance abuse or addiction, medical justification may be submitted in lieu of a plan of action, alternate pain management choices and adjuvant therapy. For patients 65 years of age, medical justification may be provided in lieu of non-opioid adjuvant drugs. Indicate how long patient will require treatment with Sustained Release Opioid Agonists SROAs ; . You must indicate whether drug is intended for PRN use. SROAs are not for short-term pain management 10 days ; or for PRN use. Indicate the type of pain and severity. SROAs are not intended for use with acute pain. Indicate prior and or current analgesic drugs used and alternative management choices. The patient must have had failed 30 day trials with alternative pain management therapies and non-opioid adjuvant drugs to replace or enhance analgesia, unless the patient has an approved cancer diagnosis. Indicate whether the patient has a history of substance abuse or addiction. If the answer is yes, a treatment plan a plan of action addressing continuing medical monitoring, titration, and a written signed contract for therapy ; must be attached to the request, unless the patient is a nursing home resident and oxytrol. The Trust already has a detailed action plan for reducing hospital acquired infection however, a summary paper seeking Board approval for the Trust to sign up to the initiative was discussed by the Board in July 2005. Following this, formal documentation showing the Trust's commitment to implement the initiative was completed and submitted to the DoH. Within the Trust, awareness of the programme has been raised by tabling of papers and discussion of the initiative at the Hospital Infection Control Committee HICC ; meeting in June 2005 and at the Clinical Governance and Risk Group CGRG ; meeting in August 2005. The recommendation that the initiative be project managed as a sub-group of the HICC with reports being forwarded from there to the Clinical Governance Committee was agreed. The CGRG received the information about the programme with interest but expressed concerns that the initiative would generate a significant amount of work for clinical staff at a time when staff are already hard pressed. The group recommended that the Saving Lives subgroup of the HICC carefully consider the targeted implementation of the programme within the organisation to maximise its benefits whilst minimising any extra burden it places on staff. Although this approach is consistent with the programme which recommends that the application of the assessment tool and High Impact Interventions should be done depending on local priorities, it is difficult to reconcile this with the objective of the initiative to embed Infection Prevention and Control across the organisation and increase ownership of Infection Prevention and Control issues by all staff. There is still work to do to establish the Saving Lives subgroup and develop its programme of work. An ongoing series of subgroup meetings with terms of reference and agendas needs to be developed and arranged. Once this has been done work can commence using the nine challenge self assessment and action planning tool to generate the "balanced scorecard" and decisions made about the extent of use of the High Impact Interventions. The programme aims to enable everyone to recognise and understand the contribution they can make to reducing healthcare associated infection and to embed good infection prevention and control techniques throughout the whole organisation. The programme will therefore be far reaching and the membership of the subgroup diverse. The self assessment and action planning tool is being used to identify appropriate membership of the subgroup. Prevention and control of infection is an important part of the overall risk management strategy within the Trust. This is the fourth Infection Control annual report since the formation of Gloucestershire Hospitals NHS Trust and the second since the organisation became a Foundation Trust and will highlight the progress that has been made with regard to infection control issues. Of nephrogenic diabetes insipidus including polyuria. thirst and polydipsia. Dermatologic-drying and thinning of hair. alopecia. anesthesia of skin. acne. chronic folliculitis. serosis cuss. psoriasis or its exacerbation. generalized pruritus with or without rash. cutaneous ulcers. angioedema. Autonomic-blurred vision. dry mouth, impotence sexual dysfunction; ThyroidAbnormalities-euthyroid goiter and or hypothyroidism Including mysedema accompanied by lower Ti and T' l uptake may be elevated See PRECAUTIONS I Paradoxically. rare cases of hyperthyroidism have been reported. EEG Changes-diffuse slowing. widening of the frequency spectrum. potentiation and.

KvdIoMIoi td I ass SymptOmatIC relief of anxlsty, tenlon, agitation, WrltsblllIywid insomnia associated with anxiety neuroses and tranient sItuational dlsturbance anxiety associatedwith depressivesymptomsand as a treatmentof symptomsof anxiety If such symp. tonis are a significant feature of functional or organIc disOrders.ptlculsrly geetrolntestinslor cardiovascular. Effectivenessin long-term use, i.e., more than 4 months, has not been eeessd system. by allc clinical eee th drug for the IndIvIdUal atIent of p CINtrstndSsatieuls: Knownsensftlvftyto benzodiezepfrieeoracute narrow.angl. glaucoma. W uiIngssNot recommendedin primarydepressivedisorders or psychoses.As wIth at NS. actIng drugs. warn patients on lorazepamnot to operate machineryor motor vehlcles of and dimioishedtolerancefor &cohol and other CNSdepressants. Ph and Psychdoglcst Dependence: Wfthdrsw& symptomsWisthose noted atth bwb turates and alcohol have occurred following abrupt dlscontlnuancs of benzodlazeplnes.
A t i costs a r e follows: coal 6.50 R M p ton : w a ~0-54% m o i s gasifier u n ~ pf. p e r power 1.1 pf. p e r labor a n d each w i t nnd 5 proclucers. 7h .~ ~ each 0.4 pf. p e r oxygen 2.2 pf. output of s y operatin~ con~ : p e total east of t h 3.8 pf. p e r ditions i s 1 07- million c u f ~ao~ , ~ ~ - " less a credit of 1.4 pf. Per m. ~, or a cost of 2.4 pf. u n" it. 0 p e w~th o r w~thout 0.-; t h e usual ~ per m 2 o~10.9 d. per 1, 000 cu. f t . synthesis-gas emnposition w h e 0.- i s CO, 25%. 604. ~ P i Gasification Process. H.~, 50% ; CO. 13% ; CH~, 3.5% ; ~'~, 3.5% : Without 0~: : .~ VoL 8, 19-t6, pp. 218-220. the composition i s 23%, 56c~, 10%, a n d 3 % respeetively~ G i v some d e t Pintsch-HiIlebrand process is based o n t heated circ~Uating g a s supply the necessary h e a 610. COOL, Shy G V ~ Germany, . the reaction. T w o plants a r e known : One a t H Vol. 151, 1935, p. . ! g a s brown-coal briquets nnd the other at the ~ ' e Capital cost of a F soling hydrogenation plant o f the Union rheinische 5, 400 per m e t ton of gasoline produced per day com" ~ : | Braunkoblen-Kraftstoff, which consists of 11 units, p a r e RM. 4, 000 f o r the L G. eoal-hydrogenation | each of 5.500 m 2 p hr, capacity, and uses brown-coal plant. D e p the F i s how: ' | br~qnets w i t pregasifieation s h a drive off the t a r ever, be l e s process will consume 7 : ~1 construction and operation of the plant are illustons of.coke p e r ton of gasoliue c o m tons : : | and described, and : operating r e s tabuof c0al f o r coal-hydrogeuation process. ': : | lated. Since the p l a operated, a v e r 611.--. P r o d Coke-0ven L ] u n fuel w a s eft%lent operation. : Gas Report of Utilisation of Coal Committee. ol. : | The briquets w e r suitable i f t specific g r a 153 1036 pp 330-381" I n s t Mere : 19 ] 1.23. a m o eontent of 13.5-1-1c ~, a strengtb of A p 11~36. p. o ' 14.07.150 kg. p e r era.-" 2, 000-2.500 p. s. i . and a n ash- . A p g 1936. p. 2. I Fischer: 3 .' "ith special sorteain.~ point Of not less t h a 1.2flO~-l.a00: The g a s Outline of~ t h e Fischer: Tropseli process, w i t h .speCial reference t t h n|odificat | produced w a s suitable for synthesis ga~ havin a COr.e~.erence tO t h nmdifieation by F i rr, P iichler, and c h l and I~.ol!~el, w l , erchy a sui~ab] s y ~ pr0dUced r e b sm~able ~ produced | ~I~. ratio o f about 1 : 2. Kolbel, wl s . ' blowing mixture of 605; . Thyssen-Gnlocsy Complete Gasification s t e and coke-oven g a s . exanlple, if'.10 Cu. f t . cu. f t s and .~oke-oven gas. ~ Pr0oess. VoLS. 19-]6, pp. 106-107. of coke-oven g a s w used for e v e po0nd I of steam, ] coke-ove~! use ~ : ~ results of a 4 plant e i : tthe resulting g a s would h a v cmnposition % hy ~ : resultil~g ~, ion : % d u the w a r Wmme-EickeL D u e to the hltermitv o h m I-I.; 60; CO. 30; N: and o t h gases, 1 0 For volume: I-I. 60; o f h i 10. For t e n supply of 0. conthmous operation for m r c each 1, 000 eu. ft: CO. t3 0 : ]gas, 330 cu. f t : coke-oven : ~| . eachand~lS lb: ft: e a t were s '. coke-oven. i~J : a f days w a s not possible, therefore r e s and~18 ], u. of s iwe: i used. ~as 1, 0O0 b: : : conclusive. : : : 612 : Developnieni ~12 : Devel0pnients i n S Africa. VoL : !i: | rich. VoL i: : ' 606: ~ . W Gasification Proces~ : Vol : .~ . 19-16, pp. 155"-153f: . : . ~ 1033, p. 329. ~ ~ . continu0ug gasification process whicl ~lses ~ Local r i g in. t h e Fischer-Tr0psch process h a v "~: tleen g r a Sonth A f r ~Iiniug " , i t ssteam: : andn c e m xvarious G e r plants is discussed. - " . "'; ' , " i a the blnst~ is described, ~ a n d & Refining CO ec0nomic a d v the p r o its abil-: 6!3. ~ . ~Fischer-Tropsch Pr0cess~ Prodncti0n of ' : low-grade, cheap fuels I n faet'this~is i t s Goal S p i Cracking; : .Vol ~ only Compensatory f e a its relatively poor thor- : 156, 1938, pp. 433-434. : " ~. Oocyte donation The number of treatment cycles undertaken in the United Kingdom using donated oocytes remains small, due to the practical difficulty of recruiting volunteer donors willing to undergo the time consuming and painful processes of pituitary down regulation, superovulation and transvaginal oocyte collection. Volunteers must undergo adequate counselling concerning the possible risks of the procedures, including the surgical risk of oocyte retrieval and the putative link between superovulation with gonadotrophins and the risk of ovarian cancer in later life and buy cyklokapron. A. Intensive control of blood sugar in patients with diabetes has been shown to decrease the risk of development of PVD. B. Cilostazol Pletal ; improves pain-free and maximal walking distance.
ANTINEOPLASTIC AND IMMUNOSUPPRESANTS All oral antineoplastic and immunosuppressant agents are covered under the prescription benefit if FDA approved. MISCELLANEOUS $$$$ interferon alpha-2b INTRON A KIT PA ; interferon alpha-2a ROFERON A KIT PA ; $$$$ $$$$ peg interferon alpha-2b PEG-INTRON PA ; $$$$ peg interferon alpha-2a PEGASYS PA ; --BLOOD MODIFIERS-ANTICOAGULANTS warfarin * COUMADIN NTI ; enoxaparin LOVENOX PA ; PLATELET AGGREGATION INHIBITORS cilostazol PLETAL PA ; clopidogrel * PLAVIX PA ; PA if days supply 30 dipyridamole ext. rel. aspirin AGGRENOX PA ; MISCELLANEOUS epoetin alfa PROCRIT PA ; epoetin alfa EPOGEN PA ; filgrastim G-CSF EUPOGEN PA ; phytonadione MEPHYTON aminocaproic acid * AMICAR CARDIOVASCULAR ACE INHIBITORS quinapril * ACCUPRIL captopril * CAPOTEN fosinopril * MONOPRIL lisinopril * ZESTRIL ALPHA BLOCKERS prazosin * MINIPRESS doxazosin * CARDURA terazosin * tabs only ; HYTRIN ANGIOTENSIN II ANTAGONISTS Updated on 10 2006 00 losartan COZAAR ST ; valsartan DIOVAN ST. Continued from page 1 at rest and after exercise. Detailed imaging of the atherosclerosis, often necessary to determine the best form of treatment, can be obtained with a unique type of CT scan, Magnetic Resonance Image MRI ; , or ultrasound. bypassing the blocked artery using a segment of vein taken from either the same or opposite leg, or a piece of synthetic material that is sewn to the artery above and below the point of blockage. Because of the inherent risks and difficulties of undergoing surgery, a bypass is Treating PAD: Exercise and Smoking usually reserved for patients with the worst symptoms, Most patients who experience claudication can avoid such as pain at rest or ulceration. Patients who fail surworsening symptoms gery or for whom if they stop smoking surgery is not conand walk regularly. sidered possible Studies have shown may need amputaSigns and Symptoms of PAD Mild that with an intensive tion. Leg cramping or other pain when walking, relieved walking program, However, many by resting most patients with patients can be Foot pain when elevating the legs at night claudication can dousuccessfully treat Paleness and coolness of toes and feet ble the distance they ed with angioplasare able to walk before Loss of leg hair ty with or without experiencing leg pain. stent placement. Ulcers on the base of the toes or heel pressure Patients who continue points ; smoking have a seven Gangrene fold increased risk of Severe worsening symptoms than non-smokers. These procedures use x-ray guidance to place a small catheter a thin plastic tube ; within the diseased Medical Therapy portion of the artery. For angioplasty, a very small balSince patients with PAD have an increased risk of heart loon attached to the end of the catheter is then inflated, attacks and stroke due to the development of similar stretching open the artery. The catheter and balloon are plaque in their heart, neck, and brain arteries, the immeremoved. If angioplasty alone does not work, a stent can diate treatment of high cholesterol, high blood pressure, often be placed in the diseased artery to hold it open. and other risk factors is critical in all patients. Stents are wire mesh tubes that are shaped and sized to Cholesterol-lowering medications, as well as certain fit inside the artery. When expanded, they resemble blood pressure medications, can reduce the risk of hoops on the inside of a barrel. They are left inside the worsening disease. In addition, a baby aspirin or other artery to restore blood flow see Figures 1 and 2 ; . Since medication blocking the action of platelets cells in the angioplasty and stenting require only a small incision in blood involved in blood clotting ; is beneficial for many the groin, these procedures can often be done on an outindividuals. patient basis or with only a short hospital stay. For patients whose leg symptoms limit their ability Many other novel techniques have evolved to treat to carry out their daily activities, or whose symptoms PAD when angioplasty alone is not considered the best have progressed, a medication called cilostazol * Pletal ; option. Devices exist which stretch and freeze the artery may also be effective in reducing their symptoms. to prevent re-blockage cryoplasty other devices cut away and remove obstructing plaque atherectomy ; , Angioplasty, Surgery, and Other Methods burn through plaque lasers ; , deliver special drugs to the to Reduce PAD arteries to keep them open longer drug-coated stents ; , When exercise, treatment of risk factors, and medical and create new channels for blood flow adjacent to the therapy alone are not enough, blockages in the leg arterblocked arteries subintimal subintimal angioplasty ; . ies may be repaired by both surgical and minimally While many of these techniques are new and not yet invasive non-surgical techniques. Surgery often involves * Pletal is a trademark of Otsuka Pharmaceutical Co., Ltd. Continued on page 6 2. Barnola, J. M., D. Raynaud, Y S. Korotkevich and C. Lorius. 1987. Vostok e. ice core provides 160, 000-year record of atmospheric CO 2. Nature, 329 6138 ; , 408 414. Bergin, M. H. and 8 others. 1995. The contributions of snow, fog, and dry deposition to the summer flux of anions and cations at Summit, Greenland. J. Geophys. Res., 100 D8 ; , 16, 275 16, Buzorius, G., U. Rannik, J.M. Makela, T. Vesala and M. Kulmala. 1998. Vertical aerosol particle fluxes measured by eddy co-variancetechnique using condensational particle counter. J. Aerosol Sci., 29 1 2 ; , 157 171. Buzorius, G., U. Rannik, J. M. Makela, P. Keronen, T. Vesala and M. Kulmala. 2000. Vertical aerosol fluxes measured by the eddy co-variance method and deposition of nucleation mode particles above a Scots pine forest in southern Finland. J. Geophys. Res., 105 D15 ; , 19, 905 19.
Any patients seek treatment from their primary care physician PCP ; because they are experiencing troubling symptoms. Pain is, in fact, the second most common presenting symptom in primary care practice after upper respiratory infections. Although patients frequently have acute pain that is time limited or secondary to a treatable underlying condition, a significant minority has chronic pain syndromes with more complex etiologies or illnesses eg, chronic back pain, persistent and recalcitrant headaches, fibromyalgia syndrome, osteoarthritis ; . Successful management of this pain, even when it cannot be eliminated, can have a significant impact on patients' quality of life. In treating these patients, PCPs may find it helpful to seek the assistance of specialists in the management of pain. Making preparations before you get an assignment to cover terrorism or another public health emergency can make a big difference in your physical and emotional health when the time comes. Fortunately, recommendations have been developed by.

EXHIBIT 31.2 Rule 13a-14 a ; Certification of Derica W. Rice, Senior Vice President and Chief Financial Officer CERTIFICATIONS I, Derica W. Rice, senior vice president and chief financial officer, certify that: 1. 2. I have reviewed this report on Form 10-Q of Eli Lilly and Company; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a-15 e ; and 15d-15 e and internal control over financial reporting as defined in Exchange Act Rules 13a-15 f ; and 15d-15 f for the registrant and have: a ; Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and.
Regulatory requirements impose obstacles to access. For example, Gilead has had to prepare, submit and manage over 100 unique regulatory applications, creating substantial delays in delivering drugs to patients. In some countries, governments impose substantial taxes and tariffs in some cases exceeding 10 percent ; , resulting in increases to our no-profit and reduced prices. These barriers are problematic and expensive, ultimately delaying the distribution of HIV medications. In addition, despite available funding from programs such as the President's Emergency Plan for AIDS Relief PEPFAR ; and the Global Fund to Fight AIDS, Tuberculosis and Malaria, some countries have resisted creating HIV programs that ensure effective distribution of HIV medications to patients in need. To address these barriers, Gilead has provided a non-exclusive license and technology transfer for its leading ARV therapy to 10 Indian generic companies that we believe can produce a high-quality generic version of the medication. Our Indian partners are licensed to distribute the drug to the world's least developed representing70percentof the HIV prevalence worldwide. The generic companies are free to establish pricing for their products and Gilead receives a 5 percent royalty on sales of finished product. Gilead hopes that partnering with multiple manufacturers will ensure competitive pricing among our Indian partners. These companies have experience in delivering ARVs throughout the world, a financial incentive, and a keen understanding of how to resolve political barriers to increase availability of HIV drugs for patients in the developing world. In June 2007, our partner Matrix Laboratories, Ltd. started distributing its generic version of Viread in Africa at approximately .50 per month. In comparison, Gilead offers branded Viread at per month in Africa. We continue to focus on the research and development of new therapies to help improve the lives of people living with HIV. Gilead is best known for its development of breakthrough once-daily dosing therapies, including Viread and Truvada, taken in combination with other ARVs. In 2006, Gilead with our partner Bristol-Myers Squibb launched ATRIPLA, the first complete HIV regimen available as one pill taken once-daily. Research has shown that these ARVs increase longterm efficacy with established safety profiles. A once-a-day dosing regimen can also help patients adhere to prescribed drug therapies. Gilead believes that those who innovate, invest in R&D and successfully develop drugs that otherwise would not exist should be rewarded for the value that innovation brings to patients. At the same time, we recognize the responsibility we share in pricing our innovative products at levels that will enable access to these medications in parts of the world with limited resources, including middle income countries. Our tiered pricing program helps us provide HIV therapies to more than 100, 000 patients in the developing world. Unfortunately, that number represents a small fraction of the millions of men, women and children across the globe diagnosed with the disease. In coming years, Gilead plans to monitor the success of our access programs and hopes to find additional opportunities to reach more patients. We hope other pharmaceutical companies will take similar steps to strike an appropriate balance between IP and improved access to life-saving medications around the world. The Chair: You still do? You told me that under drugs, they shut it down because it wasn't under a medical doctor. He's saying those same things apply under NHPs. Ms. Sonya Norris Committee Researcher ; : Under subsections 3 1 ; and 3 2 ; , the trials would have been allowed to continue. Mr. James Lunney: So I just wanted to address that. As far as claims being made under food are concerned, it is simply a matter of political will. There was no provision for natural health products to make claims under the drug style until the new regulations in part II of the Canada Gazette came into place. So the same procedure could be followed under a food directorate, allowing for good manufacturing practices, office inspections, and claims. Ms. Sonya Norris: Not claims. Mr. James Lunney: Well, it's a matter of political will. There were no claims either under the drug side before. The Chair: It's in the act that you can't make claims under food, other than to say that it won't cause dental caries, and that kind of thing. Anyway, there's lots of time tomorrow to go into some of these details. Mr. James Lunney: Thank you very much. The Chair: Thank you, everybody, for your attention. We actually finished a bit early. I'm sorry, but I thought I had two motions to go through and was trying to allow 15 minutes for each one. This meeting is adjourned.

Pletal dosing

© 2005-2007 Buy-online.100megsfree8.com, Inc. All rights reserved.